Search Results - "Halperin, D.M."

  • Showing 1 - 8 results of 8
Refine Results
  1. 1
  2. 2
  3. 3

    Atezolizumab plus bevacizumab in advanced Merkel cell carcinoma: A prospective study by de Sousa, L. Guimaraes, Liu, S., Bhosale, P., Altan, M., Darbonne, W., Schulze, K., Dervin, S., Yun, C., Mahvash, A., Verma, A., Futreal, A., Gite, S., Cuentas, E. Parra, Cho, W.C., Wistuba, I., Yao, J.C., Woodman, S.E., Halperin, D.M., Ferrarotto, R.

    Published in Oral oncology (01-04-2024)
    “…•In this phase II trial of atezolizumab and bevacizumab in advanced MCC patients, the ORR was 64 %, with 27 % complete responses.•Atezolizumab and bevacizumab…”
    Get full text
    Journal Article
  4. 4
  5. 5

    Clinical, pathological, and demographic factors associated with development of recurrences after surgical resection in elderly patients with neuroendocrine tumors by Shen, C., Dasari, A., Chu, Y., Halperin, D.M., Zhou, S., Xu, Y., Shih, Y.T., Yao, J.C.

    Published in Annals of oncology (01-07-2017)
    “…Incidence of locoregional neuroendocrine tumors (NETs) is rising. However, after curative resection, the patterns and risk factors associated with recurrence…”
    Get full text
    Journal Article
  6. 6

    Pre-existing Symptoms and Healthcare Utilization Prior to Diagnosis of Neuroendocrine Tumors: A SEER-Medicare Database Study by Shen, C., Dasari, A., Xu, Y., Zhou, S., Gu, D., Chu, Y., Halperin, D. M., Shih, Y. T., Yao, J. C.

    Published in Scientific reports (15-11-2018)
    “…The incidence and prevalence of neuroendocrine tumors (NETs) are continually increasing. While it is known that NET symptoms often predate diagnosis, their…”
    Get full text
    Journal Article
  7. 7

    Motivation for participating in phase 1 vaccine trials: Comparison of an influenza and an Ebola randomized controlled trial by Cattapan, A., Browne, K., Halperin, D.M., Di Castri, A., Fullsack, P., Graham, J., Langley, J.M., Taylor, B.A., McNeil, S.A., Halperin, S.A.

    Published in Vaccine (07-01-2019)
    “…Recruitment of participants into phase 1 vaccine clinical trials can be challenging since these vaccines have not been used in humans and there is no perceived…”
    Get full text
    Journal Article
  8. 8